Phase IV, Multicenter, International, Non-comparative, Open Label Study of Efficacy and Safety of Basal Bolus Therapy (Insulin Glargine + Insulin Glulisine) in Patients With T1 Diabetes Previously Uncontrolled on Any Insulin Regimen.

drug protocol number
LANTU_R_05033
drug sponsor
Sanofi
drug study
Lantus® + Apidra®
drug trial site
King Khalid University Hospital (Riyadh)
drug status
Ongoing
drug phase